Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' reply

Aliment Pharmacol Ther. 2020 Jan;51(1):192. doi: 10.1111/apt.15572.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Carcinoma, Hepatocellular*
  • Humans
  • Liver Neoplasms*
  • Niacinamide
  • Phenylurea Compounds
  • Sorafenib

Substances

  • Phenylurea Compounds
  • Niacinamide
  • Sorafenib